Research Day
EVALUATION OF PROPHYLACTIC AMIODARONE USE IN CORONARY ARTERY BYPASS GRAFT PATIENTS
Document Type
Abstract
Date
2021
Abstract
Background: Atrial fibrillation is a common arrhythmia experienced after coronary artery bypass grafting (CABG) and has been associated with longer hospital stays and complications. Amiodarone is considered to be a drug of choice for atrial fibrillation prophylaxis. This study aims to assess the difference in outcomes when CABG patients are given prophylactic amiodarone as recommended on Bronson Methodist Hospital's order set(s) as opposed to when patients are given an amiodarone regimen that differs from the order set(s) in place.
Methods: This study is an IRB approved, single-center, retrospective chart review including adult patients who received amiodarone for prophylaxis of atrial fibrillation and were admitted to Bronson Methodist Hospital in Kalamazoo, MI for CABG between January 2013 and June 30, 2019. The primary outcome is determining a difference in atrial fibrillation occurrence.
Results: A total of 100 patients were included in the final analysis with 50% having amiodarone regimens in concordance with the order set(s). The average length of stay was 8.6 days, and 68% of the patients included had a history of taking a beta-adrenergic blocking or calcium-channel blocking agent. 24% of these patients experienced perioperative atrial fibrillation, 83% of patients in this group were not given the recommended amiodarone regimen.
Concludsions: Results of this study allow Bronson Methodist Hospital to assess how well their CABG patients are being managed for the prevention of atrial fibrillation and guide future decisions regarding the CABG order set(s). We found that often adverse event endpoints were associated with non-conformity to the order set(s).